Showing 161 - 180 results of 46,725 for search '(((( 50 ng decrease ) OR ( 19 a decrease ))) OR ( 5 ((ng decrease) OR (we decrease)) ))', query time: 0.81s Refine Results
  1. 161

    Image3_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  2. 162

    Image7_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  3. 163

    Table1_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.xlsx by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  4. 164

    The Transition from a Compensatory Increase to a Decrease in C-peptide During the Progression to Type 1 Diabetes and Its Relation to Risk by Heba M Ismail (9568748)

    Published 2022
    “…Conclusions</p> <p>A transition from an increase to a decrease in AUC C-peptide approximately 1.5 years pre-diagnosis was validated in two independent cohorts. …”
  5. 165
  6. 166
  7. 167
  8. 168
  9. 169

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    “…However, there is concern that by neutralizing the SARS-CoV-2 virus, nMAbs may decrease the availability of antigens to the immune system, potentially impairing the endogenous polyclonal immune response and decreasing long-term immune protection.…”
  10. 170

    Image_1_Artesunate Alleviates Paclitaxel-Induced Neuropathic Pain in Mice by Decreasing Metabotropic Glutamate Receptor 5 Activity and Neuroinflammation in Primary Sensory Neurons.... by Yize Li (471459)

    Published 2022
    “…In conclusion, this study revealed that artesunate alleviates paclitaxel-induced hyperalgesia and spontaneous pain by decreasing DRG mGluR5 expression and neuroinflammation in the mouse model of PINP.…”
  11. 171

    Supplementary Material for: SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study by Schork A. (17795387)

    Published 2024
    “…Median glucosuria increased to 14 (10-19) g/g creatinine. At baseline, patients displayed overhydration (OH) with + 0.4 (-0.2 – 2.2) L/1.73m² which decreased by 0.5 (0.1 – 1.2) L/1.73m² after 6 months. …”
  12. 172

    Supplementary Material for: SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study by Schork A. (17795387)

    Published 2024
    “…Median glucosuria increased to 14 (10-19) g/g creatinine. At baseline, patients displayed overhydration (OH) with + 0.4 (-0.2 – 2.2) L/1.73m² which decreased by 0.5 (0.1 – 1.2) L/1.73m² after 6 months. …”
  13. 173
  14. 174
  15. 175
  16. 176
  17. 177
  18. 178

    Table_1_What have we learned from a case of convalescent plasma treatment in a two-time kidney transplant recipient COVID-19 patient? A case report from the perspective of viral lo... by Fabian Aldunate (3935021)

    Published 2023
    “…<p>Coronavirus disease 2019 (COVID-19), an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, can have a wide range of clinical manifestations, ranging from asymptomatic disease to potentially life-threatening complications. …”
  19. 179

    Image_1_What have we learned from a case of convalescent plasma treatment in a two-time kidney transplant recipient COVID-19 patient? A case report from the perspective of viral lo... by Fabian Aldunate (3935021)

    Published 2023
    “…<p>Coronavirus disease 2019 (COVID-19), an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, can have a wide range of clinical manifestations, ranging from asymptomatic disease to potentially life-threatening complications. …”
  20. 180